We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Express Scripts Holding Company (delisted) | NASDAQ:ESRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 92.33 | 92.35 | 92.56 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
09:17 ET - Regeneron and Sanofi bet they can jump-start sales of anti-cholesterol drug Praluent by slashing its price. Express Scripts, one of the largest prescription drug gatekeepers, is the first to play ball and agree to ease restrictions on patients getting the drug. Regeneron and Sanofi said in March they'd offer to cut the list price of $14,600 annually down to a range of about $4,500 to $8,000. Express Scripts will pay toward "the lower end" of that range, Chief Medical Officer Steve Miller tells Dow Jones in interview. The deal only applies to certain Express Scripts customers covering about 25 million people; but for those patients, Praluent will be the exclusive option over Amgen's Repatha. (joseph.walker@wsj.com; @joewalkerwsj)
(END) Dow Jones Newswires
May 01, 2018 09:32 ET (13:32 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Express Scripts Holding Company (delisted) Chart |
1 Month Express Scripts Holding Company (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
